Clinical trial NCT05564988: Chronic Remote Ischemic Preconditioning as a Complement to Conventional Prenatal Care for Preeclampsia
Official title: Chronic Remote Ischemic Preconditioning as a Complement to Conventional Prenatal Care for Preeclampsia: a One-center Prospective Randomized Study for Women With Non-severe Preeclampsia Between 24 and 37 Weeks' Gestation
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Preeclampsia
Keywords: Preconditioning
Lead sponsor: Centre Hospitalier Universitaire Vaudois
Sponsor class: OTHER
First posted: 2022-10-04
Enrollment: 58
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pre-eclampsia is a disease specific to pregnancy that affects 3-5% of women. It is defined by the appearance of high blood pressure after 20 weeks of amenorrhea associated with the presence of proteins in the urine, dysfunction of organs such as the liver, kidneys, lungs or brain, or dysfunction of the placenta. The cause of this disease is still unclear but it would most likely be a placental origin. Pre-eclampsia is a progressive disease that can lead to important complications. To date, there is no treatment for pre-eclampsia other than childbirth and more particularly placental delivery. Nevertheless, it is possible in some cases to stabilize arterial hypertension and thus to hope for a prolongation of the pregnancy.

Our research project aims to study the effect of preconditioning on blood pressure.

Preconditioning consists of using a blood pressure cuff and inflating it on the upper limb -like during a standard blood pressure measurement- for several minutes followed by a rest period in order to create "ischemia-reperfusion" periods. This technique would allow the release of beneficial substances into the bloodstream that would lower blood pressure. This method has been used for several years in different specialties and has produced good results on the heart, kidneys, lungs and brain.

With this technique we hope to stabilize or even reduce blood pressure in cases of pre-eclampsia and thus prolong the pregnancy.


Eligibility criteria: Inclusion Criteria:

* Singleton pregnancy
* Gestational age between 24 0/7 and 36 6/7 weeks' gestation
* Hospitalization for non-severe pre-eclampsia (non-severe hypertension = Systolic blood pressure between 140 and 160mmHg, diastolic blood pressure between 90 and 110mmHg associated with one of these: proteinuria \>=300mg/24h/thrombocytopenia 100-150G/L/central symptoms such as headache responding to standard analgesics/hyperreflexia without clonus/decreased fibrinogen/haptoglobin \<0.1/utero-placental dysfunction with IUGR and/or umbilical Doppler Class II)
* Maternal age \>18 years
* Good comprehension of French allowing easy understanding of the information protocol and the consent form

Exclusion Criteria:

* Chronic hypertension
* Renal disease
* Pre-pregnancy diabetes
* Autoimmune disease (SAPL, SLE, Sjögren)
* Severe PE (Systolic blood pressure \>160mmHg, diastolic blood pressure \>140mmHg, hepatic cytolysis at twice the norm, right hypochondrium or epigastric pain, central symptoms such as clonus or headache resistant to usual treatment or disturbed consciousness, thrombocytopenia \<100G/L, acute pulmonary edema, renal failure defined by doubling of baseline creatinine value or creatinine \>97 micromol/L)
* Suspected fetal anomaly or malformation
* HELLP syndrome
* Eclampsia attack
* Pathological fetal monitoring
* Known maternal upper limb vascular anomaly
* Severe maternal cardiac pathology
* Maternal history of deep vein thrombosis of the upper limb

Primary outcomes:
measure: Decrease blood pressure
timeFrame: Up to 13 weeks
measure: Decreased blood pressure patients
timeFrame: Up to 13 weeks
Secondary outcomes:
measure: SFLT/PLGF change
timeFrame: Up to 13 weeks
measure: Uterine artery resistance index change
timeFrame: Up to 13 weeks
Other outcomes:
Locations:
Study officials:
affiliation: CHUV
name: Hélène Legardeur
role: PRINCIPAL_INVESTIGATOR
References: